One of CYP2C8 substrates, the nonselective monoamine oxidase inhibitor phenelzine, is known to target the nervous system and is clinically prescribed as treatment for major depressive disorder (Q. Wang et al., 2019). This evidence concerns the gene CYP2C8 and major depressive disorder.